249 related articles for article (PubMed ID: 29473173)
1. Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial.
Norris PJ; Kaidarova Z; Maiorana E; Milani S; Lebedeva M; Busch MP; Custer B; Rebulla P
Transfusion; 2018 May; 58(5):1210-1217. PubMed ID: 29473173
[TBL] [Abstract][Full Text] [Related]
2. Risk of HLA antibody generation after receipt of Mirasol versus standard platelets in the MIPLATE randomized trial.
Kaidarova Z; Di Germanio C; Custer B; Norris PJ
Transfusion; 2023 Apr; 63(4):791-797. PubMed ID: 36840440
[TBL] [Abstract][Full Text] [Related]
3. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.
Saris A; Kerkhoffs JL; Norris PJ; van Ham SM; Ten Brinke A; Brand A; van der Meer PF; Zwaginga JJ
Transfusion; 2019 Feb; 59(2):470-481. PubMed ID: 30499599
[TBL] [Abstract][Full Text] [Related]
4. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
5. The challenge of platelet alloimmunization: management and prevention.
Kickler TS
Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
7. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
8. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.
Muench MO; Heitman JW; Inglis H; Fomin ME; Marschner S; Goodrich RP; Norris PJ; Jackman RP
Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210
[TBL] [Abstract][Full Text] [Related]
9. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
[TBL] [Abstract][Full Text] [Related]
10. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy.
Blundell EL; Pamphilon DH; Fraser ID; Menitove JE; Greenwalt TJ; Snyder EL; Repucci AJ; Hedberg SL; Anderson JK; Buchholz DH; Kagen LR; Aster RH
Transfusion; 1996 Apr; 36(4):296-302. PubMed ID: 8623127
[TBL] [Abstract][Full Text] [Related]
13. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
Panch SR; Guo L; Vassallo R
Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
[TBL] [Abstract][Full Text] [Related]
14. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
Mishima Y; Tsuno NH; Matsuhashi M; Yoshizato T; Sato T; Ikeda T; Watanabe-Okochi N; Nagura Y; Sone S; Kurokawa M; Okazaki H
Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
[TBL] [Abstract][Full Text] [Related]
15. The role of UV radiation in the prevention of human leukocyte antigen alloimmunization.
Andreu G; Boccaccio C; Klaren J; Lecrubier C; Pirenne F; Garcia I; Baudard M; Devers L; Fournel JJ
Transfus Med Rev; 1992 Jul; 6(3):212-24. PubMed ID: 1498466
[No Abstract] [Full Text] [Related]
16. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
Front Immunol; 2018; 9():1251. PubMed ID: 29951051
[TBL] [Abstract][Full Text] [Related]
17. UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients.
Grijzenhout MA; Aarts-Riemens MI; de Gruijl FR; van Weelden H; van Prooijen HC
Blood; 1994 Nov; 84(10):3524-31. PubMed ID: 7949107
[TBL] [Abstract][Full Text] [Related]
18. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
19. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.
Asano H; Lee CY; Fox-Talbot K; Koh CM; Erdinc MM; Marschner S; Keil S; Goodrich RP; Baldwin WM
Transplantation; 2007 Nov; 84(9):1174-82. PubMed ID: 17998874
[TBL] [Abstract][Full Text] [Related]
20. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]